Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Prostatic Neoplasms 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms by Site 1Neoplasms 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Fallopian Tube Diseases 1Endometrial Neoplasms 1Carcinoma, Pancreatic Ductal 1Adenocarcinoma 1

Interventions

Bevacizumab 40Paclitaxel 35Carboplatin 28pembrolizumab 21Cyclophosphamide 15Specimen Handling 14Cisplatin 13olaparib 11Blood Specimen Collection 11niraparib 10fludarabine 10Magnetic Resonance Spectroscopy 9Drug Therapy 9liposomal doxorubicin 8Topotecan 8Taxes 8Gemcitabine 8Biopsy 8Fulvestrant 7Doxorubicin 6cemiplimab 5abemaciclib 5Surveys and Questionnaires 5Standard of Care 5Injections 5Fluorouracil 5Cytoreduction Surgical Procedures 5trastuzumab deruxtecan 4mirvetuximab soravtansine 4aldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Ovarian Neoplasms × relacorilant × Clear all
NCT06906341 2026-04-14

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Corcept Therapeutics

Phase 2 Recruiting
270 enrolled
Gynecologic

Fallopian Tube Diseases, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡